NASDAQ:ONVO - Organovo Stock Price, Forecast & News

Organovo's stock was trading at $0.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONVO stock has increased by 11.3% and is now trading at $0.2895. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

Organovo is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Organovo.

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The medical research company had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 69.36%. View Organovo's earnings history.

News coverage about ONVO stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Organovo earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near term. View the latest news aboutOrganovo.

Organovo saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,286,300 shares, an increase of 14.9% from the February 27th total of 1,990,000 shares. Based on an average trading volume of 404,600 shares, the short-interest ratio is currently 5.7 days. Currently, 1.8% of the shares of the stock are short sold. View Organovo's Current Options Chain.

Some companies that are related to Organovo include X4 Pharmaceuticals (XFOR), Windtree Therapeutics (WINT), La Jolla Pharmaceutical (LJPC), Verona Pharma (TARA), Brainstorm Cell Therapeutics (BCLI), Dyadic International (DYAI), Solid Biosciences (SLDB), LogicBio Therapeutics (LOGC), Fennec Pharmaceuticals (FENC), Cidara Therapeutics (CDTX), Erytech Pharma (ERYP), Vaxart (VXRT), Gamida Cell (GMDA), Champions Oncology (CSBR) and Axcella Health (AXLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), Aerojet Rocketdyne (AJRD), NVIDIA (NVDA), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Exelixis (EXEL), Micron Technology (MU), Anavex Life Sciences (AVXL), Novavax (NVAX) and General Electric (GE).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Organovo's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (14.95%), Renaissance Technologies LLC (5.38%), Essex Investment Management Co. LLC (1.01%) and UBS Group AG (0.07%). View institutional ownership trends for Organovo.

ONVO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for Organovo.

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Renaissance Technologies LLC, and ARK Investment Management LLC. View insider buying and selling activity for Organovo.

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $0.29.

Organovo has a market capitalization of $37.78 million and generates $3.09 million in revenue each year. Organovo employs 70 workers across the globe. View additional information about Organovo.

The official website for Organovo is http://www.organovo.com/.

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]